Heart disease is the #1 killer of men and women in the US today. 1 of 3 women die of cardiovascular disease, specifically coronary artery disease, and it is the “silent killer” of men.Cardiovascular disease remains the leading cause of morbidity and mortality globally, making identification and assessment with management of risk factors essential for prevention and early intervention. Traditional lipid panels have long served as the cornerstone of cardiovascular risk evaluation, focusing on measurements such as total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides. These are often done by your family practitioner during yearly evaluations. However, advances in clinical research and laboratory technology have revealed significant limitations in these conventional assessments, prompting the development and widespread adoption of advanced lipid profile testing, including specialized cardiac panels offered by providers such as Access Labs. The Youth RX uses these advanced panels to identify hidden aspects of your metabolism that can lead to severe complications, enabling your physician to lower your chances of an acute event.

Beyond Standard Lipids

Advanced lipid profile testing moves past the basic measurements of LDL-C, HDL-C, and triglycerides to evaluate the quality, size, and concentration of lipoprotein particles. Studies have shown that individuals with normal LDL-C levels may still harbor increased cardiovascular risk due to elevated numbers of small, dense LDL particles, which are more atherogenic (attack the walls of your vessels more easily) than larger, buoyant LDL particles. Similarly, HDL particle number and function testing can provide additional information beyond HDL-C concentration alone.

  • Lipoprotein Particle Analysis: One of the hallmarks of advanced lipid panels is the measurement of lipoprotein particle numbers and sizes using nuclear magnetic resonance (NMR) spectroscopy or ion mobility analysis. These tests quantify LDL particle number (LDL-P), HDL particle number (HDL-P), and the distribution of small and large particles, offering insight into the true burden of atherogenic lipoproteins.
  • Apolipoproteins: Apolipoprotein B (ApoB) and Apolipoprotein A-I (ApoA-I) are critical markers included in advanced panels. ApoB reflects the total number of atherogenic lipoprotein particles (including LDL, VLDL, IDL), with elevated ApoB levels strongly associated with increased cardiovascular risk. ApoA-I, the major protein component of HDL particles, is linked to protective effects against atherosclerosis.
  • Lipoprotein(a) [Lp(a)]: Lp(a) is a genetically determined lipoprotein variant that significantly increases the risk of atherosclerosis and thrombosis. Standard lipid panels do not measure Lp(a), but advanced cardiac panels routinely include this marker, which is particularly important for individuals with a family history of premature CVD or unexplained high cardiovascular risk.
  • Remnant Cholesterol and Non-HDL Cholesterol: Remnant cholesterol, representing cholesterol content of triglyceride-rich lipoproteins, and non-HDL cholesterol (total cholesterol minus HDL-C) are emerging as strong predictors of residual cardiovascular risk. These markers are often included in advanced profiles to help identify patients who may benefit from intensified lipid-lowering therapy.
  • Advanced Inflammatory Markers: Cardiac panels may also assess biomarkers of inflammation such as high-sensitivity C-reactive protein (hs-CRP), myeloperoxidase (MPO), and fibrinogen. Chronic inflammation plays a pivotal role in the initiation and progression of atherosclerosis, and these markers can help stratify risk and guide therapeutic decision-making.
  • Genetic and Metabolic Risk Factors: Some panels incorporate genetic risk scores or tests for inherited conditions like familial hypercholesterolemia or variations in genes affecting lipid metabolism (e.g., PCSK9, LDLR, APOE). Additionally, tests for insulin resistance (such as the Lipoprotein Insulin Resistance Index) and metabolic syndrome markers are increasingly available.

CardioPro Basic Panel CP1

Advanced panel with multiple markers for cardiac disease measured, including lipoprotein particles and inflammatory indices, generally not included in standard cholesterol testing.

CardioPro Advanced Panel CP2

14 markers for cardiac disease, including the CardioPro Summary and graph, depicting overall risk based on multiple markers.

CardioPro Advanced Plus Panel CP3

52 markers for overall health and cardiac risk, including CardioPro summary and graph depicting overall risk with each marker, and Cardio IQ lipoprotein Fraction

Sample Collection and Laboratory Methods

The Youth RX in conjunction with Access Labs and similar providers, utilizes state-of-the-art methodologies such as NMR spectroscopy, mass spectrometry, and immunoassays to ensure accurate and reproducible results. Sample collection is typically performed using standard venipuncture, with results available within a few days. The blood draw can be done at our office, or in the comfort of your home or blood testing center near you.

The integration of advanced lipid profiling and cardiac panels into clinical practice represents a significant step toward personalized cardiovascular care. By identifying unique risk factors and tailoring interventions, clinicians can achieve better outcomes and reduce the risk of cardiac event.